TY - JOUR
T1 - Electrophysiology of ethmozine® (moricizine HCl) for ventricular tachycardia
AU - Wyndham, Christopher R.C.
AU - Pratt, Craig
AU - Mann, David E.
AU - Winkle, Roger A.
AU - Somberg, John
AU - De Maria, Anthony N.
AU - Josephson, Mark E.
PY - 1987/10/16
Y1 - 1987/10/16
N2 - Moricizine HCl, an antiarrhythmic phenothiazine drug, was investigated for its efficacy against ventricular tachycardia (VT) in a group of 60 patients from 8 institutions using electrophysiologic testing before and after oral administration. Moricizine HCl significantly prolonged PR, QRS, AH and HV intervals and cycle length for atrioventricular nodal block, but had minimal or no effect on repolarization or cardiac refractory periods. Induction of sustained VT (in 33 patients) and nonsustained VT (in 14 patients) occurred at baseline. During moricizine HCl therapy, sustained VT was induced in 31 patients and nonsustained VT in 7 patients. In individual patients, suppression of VT induction was obtained in 18% of patients with sustained VT and in 27% of patients with nonsustained VT. Cycle length of induced VT was significantly prolonged by moricizine HCl therapy. During prospective follow-up of 37 patients, electrophysiologic study predicted recurrence or nonrecurrence of VT with a sensitivity value of 82% and specificity of 65%.
AB - Moricizine HCl, an antiarrhythmic phenothiazine drug, was investigated for its efficacy against ventricular tachycardia (VT) in a group of 60 patients from 8 institutions using electrophysiologic testing before and after oral administration. Moricizine HCl significantly prolonged PR, QRS, AH and HV intervals and cycle length for atrioventricular nodal block, but had minimal or no effect on repolarization or cardiac refractory periods. Induction of sustained VT (in 33 patients) and nonsustained VT (in 14 patients) occurred at baseline. During moricizine HCl therapy, sustained VT was induced in 31 patients and nonsustained VT in 7 patients. In individual patients, suppression of VT induction was obtained in 18% of patients with sustained VT and in 27% of patients with nonsustained VT. Cycle length of induced VT was significantly prolonged by moricizine HCl therapy. During prospective follow-up of 37 patients, electrophysiologic study predicted recurrence or nonrecurrence of VT with a sensitivity value of 82% and specificity of 65%.
UR - http://www.scopus.com/inward/record.url?scp=0023162255&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023162255&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(87)90724-7
DO - 10.1016/0002-9149(87)90724-7
M3 - Article
C2 - 3310588
AN - SCOPUS:0023162255
SN - 0002-9149
VL - 60
SP - 67
EP - 72
JO - The American Journal of Cardiology
JF - The American Journal of Cardiology
IS - 11
ER -